In addition, hormone replacement therapy, commonly used for conventional adenomyosis patients, is contraindicated in those with CI, because long-term hormone replacement therapy may elevate CA125 levels and may increase the risk of CI.[14]. The gene discussed is MUC16; the disease is adenomyosis.